VYNE Therapeutics (VYNE) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free VYNE Stock Alerts $2.54 -0.01 (-0.39%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 7:28 AM | americanbankingnews.comVYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 30.0% in MayMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline ProgressionMay 9, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical PipelineMay 9, 2024 | investorplace.comVYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comVYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comVYNE Therapeutics receives FDA approval for trial of VYN202May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical DataMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics Amidst Favorable IND Clearance and Promising VYN202 DevelopmentMay 6, 2024 | globenewswire.comVYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET InhibitorMay 1, 2024 | globenewswire.comVYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual MeetingApril 13, 2024 | finance.yahoo.comVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth PlansMarch 19, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2024 | globenewswire.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 7, 2024 | seekingalpha.comWall Street Breakfast Podcast: NYCB Gets $1B Investment BoostMarch 3, 2024 | finance.yahoo.comVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagFebruary 29, 2024 | markets.businessinsider.comBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical DevelopmentsFebruary 29, 2024 | finanznachrichten.deVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateFebruary 27, 2024 | finance.yahoo.comVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumFebruary 27, 2024 | globenewswire.comVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumFebruary 21, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 21, 2024 | globenewswire.comVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 2, 2024 | finance.yahoo.comFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired StockJanuary 10, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial ResultsJanuary 3, 2024 | finance.yahoo.comVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of DirectorsNovember 20, 2023 | msn.comVYNE Therapeutics says director Lepore buys 13K shares in coNovember 14, 2023 | finance.yahoo.comCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics IncNovember 13, 2023 | msn.comVYNE Therapeutics files to sell 36.27M shares for holdersNovember 13, 2023 | finanznachrichten.deVYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | benzinga.comRecap: VYNE Therapeutics Q3 EarningsNovember 13, 2023 | msn.comVYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1MNovember 13, 2023 | finance.yahoo.comVYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 12, 2023 | markets.businessinsider.comPromising Vitiligo Treatment Trials and Increased Diagnosis Rates Boost VYNE Therapeutics’ Buy Rating: An OverviewNovember 9, 2023 | investing.comVYNE Therapeutics secures $88M PIPE deal to advance clinical programsNovember 7, 2023 | finance.yahoo.comVYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023November 3, 2023 | msn.comCellectis, VYNE Therapeutics among healthcare moversNovember 1, 2023 | finance.yahoo.comVYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 MillionNovember 1, 2023 | msn.comVYNE Therapeutics (VYNE) Price Target Increased by 17.86% to 16.83October 31, 2023 | benzinga.comNasdaq Gains Over 1%; McDonald's Reports Upbeat EarningsOctober 30, 2023 | msn.comWall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed MeetingOctober 30, 2023 | benzinga.comDow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two CompaniesOctober 30, 2023 | benzinga.comCrude Oil Falls Over 3%; Miromatrix Medical Shares Spike HigherOctober 30, 2023 | marketwatch.comVYNE Therapeutics Shares Rise 51% After Positive Data for Vitiligo TreatmentOctober 30, 2023 | benzinga.comWhy Vyne Therapeutics Stock Is ClimbingOctober 30, 2023 | msn.comJKS, CHRS and BMRA are among pre market gainersOctober 30, 2023 | markets.businessinsider.comVYNE Therapeutics Announces Positive Pre-clinical Data For Its VYN202October 30, 2023 | marketwatch.comVYNE Therapeutics Sees Positive Data for VYN201, VYN202October 30, 2023 | finance.yahoo.comVYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental VitiligoOctober 30, 2023 | finance.yahoo.comVYNE Therapeutics Announces Private Placement of $88 MillionOctober 30, 2023 | finance.yahoo.comVYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202 Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now VYNE Media Mentions By Week VYNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYNE News Sentiment▼1.290.76▲Average Medical News Sentiment VYNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYNE Articles This Week▼31▲VYNE Articles Average Week Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NXTC News Today KZR News Today MNOV News Today HOOK News Today SGMT News Today RAPT News Today INCR News Today RZLT News Today IMAB News Today GOSS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYNE) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
